Skip to content

Response to Rotavirus Vaccine in Infants in Ho Chi Minh City in Vietnam

An Open Single-arm Interventional Study to Identify the Influence of Human Genetic Variation on Early Transcriptional Responses and Protective Immunity Following Immunization With Rotarix Rotavirus Vaccine in Infants in HCM City in Vietnam

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03587389
Enrollment
818
Registered
2018-07-16
Start date
2019-03-19
Completion date
2022-08-08
Last updated
2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rotavirus, Diarrhea

Keywords

Rotavirus, Vaccine, Diarrhea, Host genetics

Brief summary

The primary objective is to measure the effect of host human genetics on the resulting immunological responses and long-term protection following rotavirus immunization of a study population of infants in Ho Chi Minh City, Vietnam. The secondary objectives are to assess the temporal immunological responses following rotavirus vaccination, and to investigate the role of maternally derived antibodies, and other factors that could potentially affect immunological responses following rotavirus vaccination. Also to assess infecting rotavirus genotypes in the vaccine failure cases.

Detailed description

This study will be an open single arm, single centre, interventional study conducted in Ho Chi Minh City, Vietnam. A sample size of 1,000 infants will be recruited to the study between 8 to 9 weeks (which is around 2 months) of age. These infants will receive two doses of the rotavirus vaccine, Rotarix with an interval of 28-37 days (or 4-5 weeks). The parents will be requested to bring the infants 2-3 days following each Rotarix vaccination to receive the standard EPI vaccinations. The infants will then be under passive and active surveillance for rotavirus-associated diarrhoea until 18 months of age. Blood samplings during pre and post vaccination and at 6, 12 and 18 month old visits will be collected.

Interventions

BIOLOGICALRotarix vaccine

In this study, the 1st dose of Rotarix vaccine will be administered when infants are at ages between weeks 8-9 and the 2nd dose is 28-37 days after the 1st dose, which means that there is an interval of 28-37 days or 4-5 weeks between doses. A reminding call will be set at about 4 weeks after the 1st dose to remind parents to bring their children back to Hung Vuong Hospital for the 2nd dose of Rotarix to ensure the completion of the 2nd dose of Rotarix vaccine.

Sponsors

Hung Vuong Hospital
CollaboratorOTHER
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
CollaboratorOTHER
Children's Hospital Number 1, Ho Chi Minh City, Vietnam
CollaboratorOTHER
Wellcome Sanger Institute
CollaboratorOTHER
Oxford University Clinical Research Unit, Vietnam
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
8 Weeks to 9 Weeks
Healthy volunteers
Yes

Inclusion criteria

* Infants (both males and females) between 8 and 9 weeks (i.e. approximately 2 months) of age who are attending Hung Vuong Hospital to receive their standard EPI vaccinations. * Currently registered residents of Districts 5 (where Hung Vuong Hospital is located) or 1, 6, 8, 10, or 11 (districts that are neighbouring district 5) in Ho Chi Minh city, with no specific intention of relocating in the next 12 months. * Informed consent to be enrolled in the study and comply with study procedures, including host genetic studies.

Exclusion criteria

* Refusal of consent. * Parent/ guardian under the age of 18. * Premature (i.e. gestation period \<37 weeks). * Infants who have already been immunized with either a rotavirus vaccine or the standard 2-month EPI vaccinations. * History of hypersensitivity to any components of the vaccine or adverse vaccine event. * History of intussusception or congenital malformation of the gastrointestinal tract in the child that is likely to predispose child to intussusception. * History of severe combined immunodeficiency disease (SCID), acquired immune deficiency syndrome (AIDS) or Human immunodeficiency virus (HIV) positivity, or other known immunodeficiency syndromes that may place the child at risk during immunisation.

Design outcomes

Primary

MeasureTime frameDescription
The rotavirus vaccine failure events during the time period from recruitment to 18 months of age.from the recruitment to 18 months of age after the first dose of vaccinationThe primary endpoint is to measure the proportion of rotavirus vaccine failure events during the time period from recruitment to 18 months of age after the first dose of vaccination.

Secondary

MeasureTime frameDescription
Quantification of the antibody response following immunizationdata collected during 7 site visits (Visit 1: Rotarix Dose 1, Visit 2: 2-3 after Visit 1, Visit 3: 28-37 days after Visit 1, Visit 4: 2-3 days after Visit 3, Visit 5: 6 months old, Visit 6: 12 months old, Visit 7: 18 months old)The temporal kinetics of rotavirus-specific antibody responses following immunization will be measured using virus-binding enzyme-linked immunosorbent assay (ELISA), which will be used to investigate the effect of host genetics, maternally transferred antibodies, and geospatial and epidemiological factors on the humoral response following vaccination.
Assessment of infecting rotavirus genotypes in vaccine failure casesfrom the recruitment to 18 months of age after the first dose of vaccinationThe rotavirus genotypes in vaccine failure cases will be assessed to investigate whether vaccine failure cases are a result of varying rotavirus genotypes.

Countries

Vietnam

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026